XML 39 R27.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Revenue- Incyte Corporation (Details)
$ in Thousands
 1 Months Ended 3 Months Ended 6 Months Ended 24 Months Ended 75 Months Ended
Mar. 31, 2023
USD ($)
Jan. 31, 2022
USD ($)
Mar. 31, 2024
USD ($)
Mar. 31, 2023
USD ($)
Jun. 30, 2019
USD ($)
Dec. 31, 2018
USD ($)
Mar. 31, 2024
USD ($)
Dec. 31, 2023
USD ($)
Jul. 31, 2022
USD ($)
Dec. 31, 2019
USD ($)
performanceObligation
Collaboration And Other Agreements [Line Items]                    
Revenues     $ 9,104 $ 24,496            
Deferred revenue, current     22,837       $ 22,837 $ 21,651    
Deferred revenue, net of current portion     56,182       56,182 59,243    
Incyte Corporation | Incyte MGA012 Agreement                    
Collaboration And Other Agreements [Line Items]                    
Non-refundable upfront payment         $ 150,000          
Potential commercial milestone payments under agreement                   $ 330,000
Potential development and regulatory milestone payments under agreement                   435,000
Development and regulatory milestones recognized $ 15,000           115,000      
Collaborative agreement transaction price                   $ 154,000
Variable consideration recognized           $ 4,000        
Number of performance obligations | performanceObligation                   2
Minimum | Incyte Corporation | Incyte MGA012 Agreement                    
Collaboration And Other Agreements [Line Items]                    
Potential proceeds from royalties (percent)         15.00%          
Maximum | Incyte Corporation | Incyte MGA012 Agreement                    
Collaboration And Other Agreements [Line Items]                    
Potential proceeds from royalties (percent)         24.00%          
Revenues From License Agreements | Incyte Corporation | Incyte MGA012 Agreement                    
Collaboration And Other Agreements [Line Items]                    
Revenues     200 15,000 $ 150,000          
Revenues From License Agreements | Incyte Corporation | Incyte MGA012 Clinical Services                    
Collaboration And Other Agreements [Line Items]                    
Revenues     100 1,300            
Revenues From License Agreements | Incyte Corporation | Incyte Commercial Supply Agreement                    
Collaboration And Other Agreements [Line Items]                    
Revenues     400 0            
RevenuesFromCMOAgreementsMember | Incyte Corporation                    
Collaboration And Other Agreements [Line Items]                    
Non-refundable upfront payment   $ 10,000                
Annual Fixed Payments   $ 14,400                
Revenues     2,100 $ 3,600            
Deferred revenue     $ 6,100       $ 6,100 $ 7,000    
RevenuesFromCMOAmendmentAgreement | Incyte Corporation                    
Collaboration And Other Agreements [Line Items]                    
Annual Fixed Payments                 $ 19,500  
Additional Payments                 $ 5,100  
Manufacturing Services | Incyte Corporation                    
Collaboration And Other Agreements [Line Items]                    
Extension term                 1 year  
Manufacturing Services | Incyte Corporation | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-02-01                    
Collaboration And Other Agreements [Line Items]                    
Revenue, remaining performance obligation, expected timing of satisfaction   3 years